Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT

Brief summary (registry, in English)

To assess the value of deep NGS-MRD detection for risk stratification in adult high-risk acute myeloid leukemia (AML) patients, in this prospective, single-center, observational cohort study following allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 169 patients will be enrolled, and deep NGS-MRD testing will be performed at approximately +3 months after transplantation. Patients will be stratified into NGS-MRD-positive and NGS-MRD-negative groups based on test results. No investigational interventions will be administered. Follow-up analyses will evaluate the associations between NGS-MRD status and post-transplant relapse and survival.

What you commit to

• Study type: Observational
• Planned participants: 169
• From 19 Oct 2026 to the primary completion date, 19 Oct 2027
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high-risk acute myeloid leukemia (AML) who have had a donor stem cell transplant. Deep NGS-MRD testing is done about 3 months after transplant. No study treatment is given.

Age

18 years or older

Sex

All sexes can join.

Disease stage

High-risk AML: adverse group by the 2022 ELN risk classification, or no molecular remission or MRD positive before transplant. KPS score of 60 or more.

Earlier treatment

Must have had an allogeneic hematopoietic stem cell transplant (allo-HSCT).

Biomarker or test result

NGS-MRD (measurable residual disease) is tested about 3 months after transplant. Patients are grouped as NGS-MRD-positive or NGS-MRD-negative.

Main reasons for not taking part

• Signs of relapse at 3 months after transplant (on morphology, flow cytometry or molecular tests)
• Another cancer at the same time
• Poor follow-up compliance or unable to complete NGS testing
• Other conditions the investigator decides rule out joining

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details